Nature Medicine, Published online: 10 March 2025; doi:10.1038/s41591-025-03598-7
The long-term safety of genetically modified T cells for therapeutic applications remains a crucial concern. A comprehensive analysis of 783 patients across multiple clinical trials, with >2,200 patient-years of follow-up, found no strong evidence linking these therapies to insertional oncogenesis.
